论文部分内容阅读
目的 探讨红细胞CR1基因型与红细胞调控淋巴细胞免疫粘附功能的相关性及其改变在卵巢癌发生发展过程中的作用。方法 采用PCR加HindⅢ酶切技术对 5 1例卵巢癌、46例卵巢囊肿患者及 40例正常人红细胞CR1密度相关基因型 (HH型、HL型、LL型 )进行检测 ;采用肿瘤红细胞淋巴细胞混合花环试验测定红细胞免疫粘附肿瘤细胞能力、红细胞调控淋巴细胞免疫粘附肿瘤的能力。结果 卵巢癌患者红细胞CR1基因型型别不同于正常人 ,HH型人数百分比明显低于正常人 ,HL型、LL型人数百分比则高于正常人 (P <0 0 1)。在相同基因型人群中 ,卵巢癌患者红细胞调控淋巴细胞免疫粘附肿瘤细胞能力明显低于正常人 (P <0 0 1)。结论 卵巢癌患者红细胞CR1密度基因型型别与红细胞调控淋巴细胞免疫粘附肿瘤细胞能力有关 ,其改变可能是卵巢癌发病的易患因素之一。
Objective To investigate the relationship between erythrocyte CR1 genotype and erythrocyte regulatory lymphocyte immune adhesion function and its role in the development of ovarian cancer. Methods The density-related genotypes of CR1 (HH, HL and LL) in 51 cases of ovarian cancer, 46 cases of ovarian cyst and 40 cases of normal human erythrocytes were detected by PCR and Hind Ⅲ digestion. Tumor erythrocyte lymphocyte mixture The rosette assay measures the ability of erythrocytes to immunologically adhere to tumor cells and the erythrocytes regulate the ability of lymphocytes to immunologically adhere to the tumor. Results The genotypes of erythrocyte CR1 in patients with ovarian cancer were different from those in normal subjects. The percentage of HH patients was significantly lower than that of normal subjects. The percentage of HL type and LL type was higher than that of normal people (P <0.01). In the same genotype population, the ability of erythrocyte-regulated lymphocytes to adhere to tumor cells in ovarian cancer patients was significantly lower than that in normal individuals (P <0.01). Conclusion The genotypes of erythrocyte CR1 density in patients with ovarian cancer are not related to the ability of erythrocyte to regulate lymphocyte immune adherence to tumor cells. The change may be one of the risk factors of ovarian cancer.